Emily Kendall

Assistant Professor

20092019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Emily Kendall is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 8 Similar Profiles
Tuberculosis Medicine & Life Sciences
Multidrug-Resistant Tuberculosis Medicine & Life Sciences
Vibrio cholerae O1 Medicine & Life Sciences
Bangladesh Medicine & Life Sciences
Rifampin Medicine & Life Sciences
Pharmaceutical Preparations Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Infection Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2009 2019

Empiric treatment of pulmonary TB in the Xpert era: Correspondence of sputum culture, Xpert MTB/RIF, and clinical diagnoses

Kendall, E., Kamoga, C., Kitonsa, P. J., Nalutaaya, A., Salvatore, P. P., Robsky, K., Nakasolya, O., Mukiibi, J., Isooba, D., Cattamanchi, A., Kato-Maeda, M., Katamba, A. & Dowdy, D. W., Jan 1 2019, In : PloS one. 14, 7, e0220251.

Research output: Contribution to journalArticle

Open Access
Sputum
tuberculosis
lungs
Lung
Tuberculosis
Open Access
bedaquiline
Rifampin
Pyrazinamide
Tuberculosis
Pharmaceutical Preparations

Informing decision-making for universal access to quality tuberculosis diagnosis in India: An economic-epidemiological model

Sohn, H., Kasaie, P., Kendall, E., Gomez, G. B., Vassall, A., Pai, M. & Dowdy, D. W., Aug 6 2019, In : BMC medicine. 17, 1, 155.

Research output: Contribution to journalArticle

Open Access
Economic Models
India
Decision Making
Tuberculosis
Costs and Cost Analysis

Projected population-wide impact of antiretroviral therapy-linked isoniazid preventive therapy in a high-burden setting

Kendall, E., Azman, A., Maartens, G., Boulle, A., Wilkinson, R. J., Dowdy, D. W. & Rangaka, M. X., Mar 1 2019, In : AIDS (London, England). 33, 3, p. 525-536 12 p.

Research output: Contribution to journalArticle

Isoniazid
Population
Tuberculosis
Therapeutics
Incidence

What will it take to eliminate drug-resistant tuberculosis?

Kendall, E., Sahu, S., Pai, M., Fox, G. J., Varaine, F., Cox, H., Cegielski, J. P., Mabote, L., Vassall, A. & Dowdy, D. W., May 1 2019, In : The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 23, 5, p. 535-546 12 p.

Research output: Contribution to journalArticle

Multidrug-Resistant Tuberculosis
Drug Repositioning
Point-of-Care Systems
Pharmaceutical Preparations
Rifampin